# Efficacy and Safety of Mycograb as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS

> **NCT00847678** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 38 (actual)

## Conditions studied

- Cryptococcal Meningitis

## Interventions

- **BIOLOGICAL:** Efungumab (Mycograb)
- **BIOLOGICAL:** placebo
- **BIOLOGICAL:** Amphotericin B
- **BIOLOGICAL:** 5 flucytosine

## Key facts

- **NCT ID:** NCT00847678
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-08
- **Primary completion:** 2007-11
- **Final completion:** —
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2009-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00847678

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00847678, "Efficacy and Safety of Mycograb as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00847678. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*